Drug

Rimonabant

Approved medicine

ClassCannabinoid CB1 receptor antagonistResearchOngoing clinical research

RxNorm341199 ChEMBLCHEMBL111 ATCA08AX01UNIIRML78EN3XE

Cannabinoid receptor 1

Primary target

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Efectos de un Antagonista/Agonista Inverso Del Receptor CB1 (Rimonabant) Sobre la Capacidad Para la deambulación en Lesionados Medulares Incompletos

Clinical trial2023-11-01Primary completion · ClinicalTrials.gov

Effects of Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury: a Proof-of-concept Study

Clinical trial2022-06-07Completed · ClinicalTrials.gov

Translational Center on the Clinical Neurobiology of Cannabis Addiction

Clinical trial2017-06-19Results posted · ClinicalTrials.gov

The Effect of Rimonabant on Energy Expenditure, Fat Metabolism and Body Composition

Clinical trial2010-05-01Terminated · ClinicalTrials.gov

Antagonist-Elicited Cannabis Withdrawal

Clinical trial2010-01-11Completed · ClinicalTrials.gov

Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases.

Clinical trial2009-04-01Primary completion · ClinicalTrials.gov

Randomized, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by Carotid Artery Intima-media Thickness (CIMT), in Overweight Patients With Additional Risk Factors

Clinical trial2009-04-01Terminated · ClinicalTrials.gov

Randomized, Multinational, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20 mg OD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients With Clustering Risk Factors

Clinical trial2009-04-01Terminated · ClinicalTrials.gov

A Randomized, Double-Blind, Parallel-Group, Multicenter, Multinational Study to Assess Glycemic Control With Rimonabant in Comparison With Glimepiride Over 1 Year in Overweight/Obese Type2 Diabetic Patients Not Adequately Controlled With Metformin

Clinical trial2009-03-01Terminated · ClinicalTrials.gov

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of Long-term Administration of Rimonabant in the Prevention of Type 2 Diabetes in Patients With Prediabetic Status (i.e., Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or Both)

Clinical trial2009-03-01Terminated · ClinicalTrials.gov

The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia

Clinical trial2009-03-01Terminated · ClinicalTrials.gov

A Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Non-diabetic Patients With Nonalcoholic Steatohepatitis (NASH)

Clinical trial2009-02-01Terminated · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Rimonabant

RxNorm CUI

341199

ChEMBL ID

CHEMBL111

ATC codes

A08AX01

UNII

RML78EN3XE

Primary mechanism

Cannabinoid CB1 receptor antagonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Cannabinoid receptor 1

CNR1 · P21554

ANTAGONISTCannabinoid CB1 receptor antagonist

Clinical trials

44 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2022

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 44

Phase 11Phase 1 / 21Phase 24Phase 335Phase 42Phase N / A1

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases.

Unknown statusPH IVKey trialHospital Arnau de Vilanovan=2,9482013

The Effect of Rimonabant on Energy Expenditure, Fat Metabolism and Body Composition

TerminatedPH IVUniversity of Surreyn=142010

TerminatedPH IIISanofin=6612009

TerminatedPH IIIKey trialSanofin=18,6952009

TerminatedPH IIIKey trialSanofin=2,4202009

Recent completions

Trials that read out recently, adding to the completed evidence base.

Effects of Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury: a Proof-of-concept Study

CompletedPH I/IIHospital Nacional de Parapléjicos de Toledon=82022

Translational Center on the Clinical Neurobiology of Cannabis Addiction

CompletedPH IIThe Scripps Research Instituten=662011

Antagonist-Elicited Cannabis Withdrawal

CompletedPH INational Institute on Drug Abuse (NIDA)2010

REASURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents

CompletedPH IIISanofin=3582009

Atherosclerotic Plaque Texture-Experimental and Clinical Study on the Diagnostic and Therapeutic Strategies of Atherosclerotic Plaque Vulnerability

CompletedN/AAristotle University Of Thessalonikin=3002009

A Randomized, Double Blind, Two-arm Placebo Controlled, 12-Month Study of the Effects of Rimonabant 20mg Once Daily on the Amount and the Activity of Visceral Fat in Abdominally Obese Patients With Metabolic Syndrome.

CompletedPH IIISanofin=2542008

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
ClinicalTrials.gov — clinical trials